Medication info
Rosumax Tablet 10mg (Rosuvastatin Calcium)

Rosumax Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Jeongwoo Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (15 tablets/PTP x 2 packs)
Approval status
Active

MFDS item code 201903289 · Approved 2019.05.21

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Ingredients

Manufacturer
Jeongwoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • risk of stroke
  • risk of myocardial infarction
View approved original text

This medication is used as an adjunct when dietary changes and exercise are insufficient in the control of primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunct to diet or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia, and it lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis. It can also be used as an adjunct to dietary therapy in pediatric patients aged 10 to less than 17 years with heterozygous familial hypercholesterolemia who meet specific criteria. Furthermore, it is effective as an adjunct to dietary therapy for patients with primary dysbetalipoproteinemia. Finally, it helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk groups with chronic cardiovascular disease risk factors. Thus, it is used effectively for various lipid abnormalities and the reduction of cardiovascular disease risk.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on doses higher than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Safety and efficacy have not been established in children under 10 years of age.

Precautions

This drug should not be administered to certain patients. For example, individuals allergic to this drug's components, those with severely impaired liver function, those with muscle diseases, those with significantly reduced kidney function, pregnant or nursing women, and fertile women who do not use effective contraception should not use this medication. Additionally, high doses of this drug are contraindicated in patients at risk of muscle diseases or rhabdomyolysis, and those with these risk factors should have careful evaluation and continuous monitoring before using this drug. Patients with a history of liver disease or excessive alcohol consumption should undergo liver function tests before starting this medication and receive regular liver enzyme tests during treatment. This medication can cause muscle pain, myopathy, and occasionally severe muscle rupture known as rhabdomyolysis; if symptoms such as muscle pain, weakness, or cramps arise during treatment, healthcare professionals should be notified immediately. This medication can also cause side effects such as liver function abnormalities, increased blood glucose, and rarely severe skin reactions, so any unusual symptoms should be discussed with a doctor immediately. Drug interactions may occur when used together with other medications, potentially increasing the blood concentration of this drug; therefore, it is crucial to inform the doctor or pharmacist of any co-administered medications, and some drugs should be avoided in combination. Women who are pregnant or planning to become pregnant should avoid taking this drug, and if pregnancy is confirmed during treatment, it should be discontinued immediately, and nursing mothers should also avoid using this medication for safety. There are no specific antidotes for overdose, so appropriate treatment and testing for liver function and muscle enzymes are needed based on symptoms. Caution is required when driving or operating machinery as dizziness may occur. This drug may present higher systemic exposure in Asians; therefore, dose adjustments may be necessary. Overall, this drug should be taken with careful observation of liver and muscle health, and it is essential to consult healthcare providers immediately in case of side effects.

Side effects

Hypersensitivity, angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, severe muscle weakness, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS), erythrodermic drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, fatigue, numbness, paresthesia, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (15 tablets/PTP x 2 packs)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.